NeuroPace Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
216
- Stock Symbol
-
NPCE
- Investments
-
1
- Share Price
-
$7.95
- (As of Friday Closing)
NeuroPace General Information
Description
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Contact Information
Website
www.neuropace.comCorporate Office
- 455 North Bernardo Avenue
- Mountain View, CA 94043
- United States
Corporate Office
- 455 North Bernardo Avenue
- Mountain View, CA 94043
- United States
NeuroPace Timeline
NeuroPace Stock Performance
As of 20-Nov-2026, NeuroPace’s stock price is $7.95. Its current market cap is $274M with 34.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.95 | $8.14 | $5.46 - $19.60 | $274M | 34.5M | 269K | -$0.56 |
NeuroPace Financials Summary
As of 30-Sep-2026, NeuroPace has a trailing 12-month revenue of $107M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 490,534 | 525,438 | 350,669 | 281,331 |
| Revenue | 106,746 | 99,986 | 79,906 | 65,421 |
| EBITDA | (8,442) | (14,876) | (19,598) | (25,884) |
| Net Income | (18,916) | (21,465) | (27,141) | (32,956) |
| Total Assets | 94,775 | 105,565 | 94,647 | 107,651 |
| Total Debt | 69,540 | 70,837 | 73,338 | 72,395 |
NeuroPace Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NeuroPace Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
NeuroPace Comparisons
Industry
Financing
Details
NeuroPace Competitors (9)
One of NeuroPace’s 9 competitors is BrainScope, a Venture Capital-Backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BrainScope | Venture Capital-Backed | Rockville, MD | ||||
| Finapres Medical Systems | Corporate Backed or Acquired | Enschede, Netherlands | ||||
| DexCom | Formerly VC-backed | San Diego, CA | ||||
| Emteq Labs | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Neuspera | Venture Capital-Backed | San Jose, CA |
NeuroPace Patents
NeuroPace Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260077198-A1 | Systems, devices, and methods for determining treatment for a neurological disorder | Pending | 16-Sep-2024 | ||
| US-20260273288-A1 | System and methods for determining and tuning detection settings in a neurostimulator | Pending | 22-May-2024 | ||
| US-20250359812-A1 | System and methods for proposing detection parameters for detecting epileptiform activity | Pending | 22-May-2024 | ||
| US-20250229090-A1 | Implantable medical device with a slot antenna | Pending | 12-Jan-2024 | ||
| WO-2025151324-A1 | Implantable medical device with a slot antenna | Inactive | 12-Jan-2024 | A61N1/37217 |
NeuroPace Signals
NeuroPace Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
NeuroPace Investments (1)
NeuroPace’s most recent deal was a Later Stage VC with Epicor Medical for . The deal was made on 12-May-2003.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Epicor Medical | 12-May-2003 | Later Stage VC | Other Devices and Supplies |
NeuroPace ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
NeuroPace Exits (1)
NeuroPace’s most recent exit was on 12-May-2003 from Epicor Medical. The exit was categorized as with 9 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Epicor Medical | 12-May-2003 | Completed |
|
NeuroPace FAQs
-
When was NeuroPace founded?
NeuroPace was founded in 1997.
-
Where is NeuroPace headquartered?
NeuroPace is headquartered in Mountain View, CA.
-
What is the size of NeuroPace?
NeuroPace has 216 total employees.
-
What industry is NeuroPace in?
NeuroPace’s primary industry is Diagnostic Equipment.
-
Is NeuroPace a private or public company?
NeuroPace is a Public company.
-
What is NeuroPace’s stock symbol?
The ticker symbol for NeuroPace is NPCE.
-
What is the current stock price of NeuroPace?
As of 20-Nov-2026 the stock price of NeuroPace is $7.95.
-
What is the current market cap of NeuroPace?
The current market capitalization of NeuroPace is $274M.
-
What is NeuroPace’s current revenue?
The trailing twelve month revenue for NeuroPace is $107M.
-
Who are NeuroPace’s competitors?
BrainScope, Finapres Medical Systems, DexCom, Emteq Labs, and Neuspera are some of the 9 competitors of NeuroPace.
-
What is NeuroPace’s annual earnings per share (EPS)?
NeuroPace’s EPS for 12 months was -$0.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process